In the ongoing human effort to extend and protect life after the heart falters, a year-long clinical trial presented in New Orleans has quietly shifted the ground beneath a long-standing assumption: that two widely prescribed blood-thinning medications are interchangeable for diabetic patients living with coronary stents. The TUXEDO-2 study, following 1,800 adults across India, found that prasugrel meaningfully outperformed ticagrelor in reducing heart attacks, bleeding, and death over twelve months. The findings arrive as a reminder that in medicine, as in life, the details of individual circ
Prasugrel outperforms ticagrelor in diabetic stent patients, study finds
Higher mortality and bleeding complications in ticagrelor patients (5.03% death rate vs 3.67% for prasugrel) directly impacted patient outcomes.
The two drugs should not be used interchangeably.
Mark
So the study found that prasugrel was better than ticagrelor for diabetic patients with stents. What exactly made the difference?
Mimi
The outcomes were measured across a full year after the stent was placed. Prasugrel patients had lower rates of heart attacks, major bleeding, and death. The combined adverse event rate was about 2.3 percentage points lower with prasugrel—16.57 percent versus 14.23 percent.
Luke
Those are real numbers, but I want to be careful here. We're talking about differences in the range of 1-2 percentage points on most individual outcomes. That's clinically meaningful, but it's not like one drug was dramatically superior.
Mimi
True, but the death rate difference is harder to dismiss—5.03 percent versus 3.67 percent. That's a meaningful gap in a one-year window.
Mark
Why would two drugs that are supposed to do the same thing produce different results in diabetic patients specifically?
Mimi
The study doesn't explain the mechanism. It just shows that in this population—people with diabetes and complex coronary disease—prasugrel performed better. The researchers were surprised by the finding themselves.
Luke
And we should note: this is one study from India with 1,800 participants. It's a solid trial, but it's not yet the kind of evidence that would automatically change global guidelines. The findings need to be replicated.
Mark
The study mentions that certain subgroups had even bigger differences—people newly diagnosed with diabetes and those at high bleeding risk.
Mimi
Right. In patients with diabetes for less than five years, the risk of adverse events was 63 percent higher on ticagrelor. In high-bleeding-risk patients, it was 61 percent higher. Those are substantial differences that suggest prasugrel might be especially valuable in those populations.
Luke
But again, those are subgroup analyses. They're suggestive, but they're not the primary finding. Subgroup results can be unstable and sometimes don't hold up in follow-up studies.
Mark
What about the limitations the researchers acknowledged?
Mimi
The big one is that neither patients nor doctors were blinded to which drug was assigned. That could introduce bias—expectations might influence how people report symptoms or how doctors manage side effects.
Luke
And they didn't track medication adherence. We don't actually know if people took their pills as prescribed. That's a significant gap when you're comparing two drugs.
Mark
So what happens next?
Mimi
The trial continues following these patients for five years total. More data will come. And presumably other researchers will want to test whether these findings hold in different populations—maybe in Europe or North America, where the patient mix and healthcare systems differ.
The Pulse
- A foundational assumption in cardiology — that ticagrelor and prasugrel work equally well in diabetic stent patients — has been directly contradicted by one of the largest trials of its kind.
- The human cost is not abstract: ticagrelor patients died at a rate of 5.03% versus 3.67% for prasugrel, and suffered more heart attacks and major bleeding over the same twelve-month period.
- Certain patients faced even steeper odds on ticagrelor — those newly diagnosed with diabetes and those already vulnerable to bleeding were roughly 1.6 times more likely to experience serious adverse events.
- The study's lead author, who initially expected ticagrelor to perform at least as well, now calls for an end to treating these drugs as interchangeable in diabetic populations.
- Current cardiology guidelines recommending either drug for stent patients may require revision, as the evidence now points toward personalized antiplatelet selection as a meaningful clinical imperative.
In the ongoing human effort to extend and protect life after the heart falters, a year-long clinical trial presented in New Orleans has quietly shifted the ground beneath a long-standing assumption: that two widely prescribed blood-thinning medications are interchangeable for diabetic patients living with coronary stents. The TUXEDO-2 study, following 1,800 adults across India, found that prasugrel meaningfully outperformed ticagrelor in reducing heart attacks, bleeding, and death over twelve months. The findings arrive as a reminder that in medicine, as in life, the details of individual circumstance can matter more than the comfort of broad equivalence.
A clinical trial presented at the American Heart Association's Scientific Sessions in New Orleans this November challenged a deeply embedded assumption in cardiology: that ticagrelor and prasugrel — two powerful antiplatelet drugs — perform equally well in diabetic patients who have received coronary stents. The TUXEDO-2 study followed 1,800 adults with type 1 or type 2 diabetes across 66 hospitals in India, all of whom had multivessel coronary disease and were randomly assigned to one of the two medications alongside aspirin for one year.
The results were difficult to dismiss. Patients on ticagrelor experienced adverse events — including heart attack, stroke, major bleeding, or death — at a rate of 16.57%, compared to 14.23% for those on prasugrel. The mortality gap was particularly striking: 5.03% of ticagrelor patients died within the year, versus 3.67% of those on prasugrel. Major bleeding complications also favored prasugrel, appearing in 7.14% of its patients against 8.41% for ticagrelor.
Lead author Sripal Bangalore of NYU Langone acknowledged that the findings contradicted his team's original hypothesis. Certain subgroups revealed the sharpest contrasts: patients diagnosed with diabetes for fewer than five years faced 1.63 times the risk of adverse events on ticagrelor, and those already at high bleeding risk fared 1.61 times worse on the same drug.
The trial was not without limitations — neither patients nor physicians were blinded to their assigned medication, and medication adherence was not directly monitored. Yet the magnitude of the differences, particularly in mortality and bleeding, points toward a genuine pharmacological distinction. With the broader study continuing to track participants for five years, more data will follow — but for now, the message is clear: for diabetic patients navigating complex coronary disease, the choice of antiplatelet therapy may carry far more consequence than current guidelines acknowledge.
A year-long clinical trial presented in New Orleans this November upended a widely held assumption in cardiology: that two powerful blood-thinning drugs work equally well in diabetic patients who have had stents placed in their coronary arteries. The study, called TUXEDO-2, followed 1,800 adults across 66 hospitals in India—all with type 1 or type 2 diabetes and blockages in multiple heart vessels—who received drug-eluting stents and were randomly assigned to take either ticagrelor or prasugrel alongside aspirin for a full year. When researchers tallied the results, the difference was stark enough to challenge clinical practice.
Patients on ticagrelor experienced adverse events—heart attack, stroke, major bleeding, or death—at a rate of 16.57 percent. Those taking prasugrel had a 14.23 percent rate. The gap widened when researchers looked at individual outcomes. Nonfatal heart attacks struck 5.96 percent of the ticagrelor group versus 5.21 percent of prasugrel patients. Major bleeding complications appeared in 8.41 percent taking ticagrelor compared to 7.14 percent on prasugrel. Most sobering: the one-year death rate was 5.03 percent for ticagrelor patients and 3.67 percent for those on prasugrel. The findings were presented as a late-breaking session at the American Heart Association's Scientific Sessions 2025.
Sripal Bangalore, the study's lead author and director of research at NYU Langone's Cardiac Catheterization Laboratory, said the results contradicted the team's initial hypothesis. "We initially thought ticagrelor would be equally effective, if not better," he explained. The discovery forced a recalibration of how cardiologists should think about these medications. "These drugs are often considered interchangeable, but our findings suggest important differences," Bangalore said. "For individuals with type 1 or type 2 diabetes and complex coronary disease, prasugrel may offer distinct advantages over ticagrelor."
The trial enrolled adults with an average age of 60—71 percent men and 29 percent women. About a quarter were insulin-dependent, roughly 79 percent had acute coronary artery syndrome, and approximately 85 percent had disease in all three major coronary vessels. The study's design was rigorous: participants were randomly assigned to receive one of two types of drug-eluting stents and one of two antiplatelet regimens. The two treatment groups were balanced across age, sex, ethnicity, and baseline heart health measures.
Certain subgroups showed particularly pronounced differences between the drugs. Patients who had been diabetic for fewer than five years fared worse on ticagrelor—their risk of adverse events was 1.63 times higher than those on prasugrel. Similarly, patients at high risk for bleeding complications experienced 1.61 times more adverse events on ticagrelor. These findings suggest that prasugrel may be especially protective in newly diagnosed diabetics and those vulnerable to hemorrhage, populations where the choice of antiplatelet agent could meaningfully alter outcomes.
The study was conducted between 2020 and 2024 at Indian hospitals, part of a larger investigation into optimal strategies for treating coronary artery disease in diabetic patients with multivessel disease. The primary trial continues to follow participants for approximately five years after stent implantation, meaning more data will emerge. Current guidelines recommend dual antiplatelet therapy—aspirin plus a P2Y12 inhibitor like ticagrelor or prasugrel—for at least one year in all patients receiving drug-eluting stents, but the TUXEDO-2 findings suggest that blanket recommendation may need refinement for diabetic populations.
The study had limitations. Neither patients nor physicians were blinded to which medication was assigned, opening the door to bias. Researchers also did not monitor whether participants actually took their medications as prescribed, leaving some uncertainty about adherence. Still, the magnitude of the differences—particularly in mortality and bleeding rates—suggests a real pharmacological distinction rather than noise in the data. Bangalore emphasized the need for a more tailored approach: "The two drugs should not be used interchangeably." For the thousands of diabetic patients receiving stents each year, the choice between these two medications may now carry more weight than previously recognized.
Notable Quotes
Our results suggest that prasugrel may be the better choice for patients with type 1 or type 2 diabetes.— Sripal Bangalore, lead author, NYU Langone Cardiac Catheterization Laboratory
For individuals with type 1 or type 2 diabetes and complex coronary disease, prasugrel may offer distinct advantages over ticagrelor. This research highlights the need for a more personalized approach to treatment.— Sripal Bangalore
Want the full story?
Read the original at News-Medical.net ↗
Health & Medicine